ArticleTherapeutic advances in musculoskeletal disease2026
Malignancy risk in patients with rheumatoid arthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a 5-year population-based cohort study.
Article in Therapeutic advances in musculoskeletal disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Data regarding malignancy risk amongst rheumatoid arthritis (RA) patients using biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) was conflicting, and real-world Taiwanese data was lacking. Objectives: To compare the malignancy risk and to investigate factors associated with malignancies amongst RA patients initiating b/tsDMARDs. Design: Nationwide, population-based, retrospective cohort study. Methods: We conducted a retrospective cohort study using the Taiwan National Health Insurance Research Database from 2001 to 2020. Adult patients with newly diagnosed, biologic-naïve RA were included if they initiated b/tsDMARDs, and those with prior malignancies were excluded. The primary outcome was the first diagnosis of malignancies after b/tsDMARD initiation. Time-dependent Cox proportional hazards models were performed to evaluate malignancy risk across different b/tsDMARDs and to identify independent risk factors. Results: A total of 8732 adult RA patients were included. Over both 5-year and extended 18-year follow-up periods, there was no statistically significant difference in malignancy risk amongst the four treatment groups (tumour necrosis factor inhibitors (TNFis), tocilizumab, abatacept and tsDMARDs). Independent associated factors included male gender, older age at b/tsDMARD initiation, chronic lung diseases including chronic obstructive pulmonary disease and higher-dose corticosteroid prescription. Use of conventional DMARDs and more frequent ambulatory follow-up were associated with a lower risk. Conclusion: In this Taiwanese nationwide RA cohort, b/tsDMARD class demonstrated no difference in malignancy risk within 5 years after their initiation. Clinicians should instead focus on individual associated factors, particularly male gender, older age at b/tsDMARD initiation, chronic lung diseases and higher-dose corticosteroid exposure, while optimising the protective role of conventional DMARDs and regular follow-up for better disease control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.